Artelo Biosciences公布的中期试验结果显示，在每日剂量高达1300微克的用药方案下，受试者的体重、瘦体重（肌肉量）以及活动能力均呈现出积极改善趋势，同时治疗耐受性良好，未出现重大安全性问题。这些数据为该公司相关候选药物的进一步开发提供了支持性证据。
Artelo Biosciences公布的中期试验结果显示，在每日剂量高达1300微克的用药方案下，受试者的体重、瘦体重（肌肉量）以及活动能力均呈现出积极改善趋势，同时治疗耐受性良好，未出现重大安全性问题。这些数据为该公司相关候选药物的进一步开发提供了支持性证据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.